Human Papillomavirus (HPV) Associated Cancer Pipeline Landscape Report 2021 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Human Papillomavirus (HPV) Associated Cancer (Oncology) – Drugs In Development, 2021” report has been added to ResearchAndMarkets.com’s offering.

Human Papillomavirus (HPV) Associated Cancer – Drugs In Development, 2021, provides an overview of the Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline landscape.

Human papillomavirus (HPV) is the most common viral infection of the reproductive tract. Human papillomavirus (HPV) has been found to be associated with several types of cancer. Risk factors include smoking, weakened immune system, long-term oral contraceptive use and chronic inflammation. Human papillomavirus (HPV) associated cancer have no symptoms until it is quite advanced, very serious and hard to treat.

Report Highlights

Human Papillomavirus (HPV) Associated Cancer – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Human Papillomavirus (HPV) Associated Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Human Papillomavirus (HPV) Associated Cancer and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 29, 17, 40, 7 and 2 respectively.

Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 1, 12 and 2 molecules, respectively. Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.- Find and recognize significant and varied types of therapeutics under development for Human Papillomavirus (HPV) Associated Cancer (Oncology).- Classify potential new clients or partners in the target demographic.- Develop tactical initiatives by understanding the focus areas of leading companies.- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.- Formulate corrective measures for pipeline projects by understanding Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline depth and focus of Indication therapeutics.- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

1. Introduction
2. Human Papillomavirus (HPV) Associated Cancer – Overview
3. Human Papillomavirus (HPV) Associated Cancer – Therapeutics Development
4. Human Papillomavirus (HPV) Associated Cancer – Therapeutics Assessment
5. Human Papillomavirus (HPV) Associated Cancer – Companies Involved in Therapeutics Development
6. Human Papillomavirus (HPV) Associated Cancer – Drug Profiles
7. Human Papillomavirus (HPV) Associated Cancer – Dormant Projects
8. Human Papillomavirus (HPV) Associated Cancer – Discontinued Products
9. Human Papillomavirus (HPV) Associated Cancer – Product Development Milestones
10. Appendix

Companies Mentioned

• Abion Inc
• Abivax SA
• Advaxis Inc
• Anteris Technologies Ltd
• Antiva Biosciences Inc
• Apimeds Inc
• Astex Pharmaceuticals Inc
• AstraZeneca Plc
• Atara Biotherapeutics Inc
• Auro Vaccines LLC
• Avalia Immunotherapies Ltd
• Avidea Technologies Inc
• Beijing Recreation Guards Biotechnology Co Ltd
• Beijing Shenzhou Cell Biotechnology Group Co Ltd
• BioMed Valley Discoveries Inc
• Biond Biologics Ltd
• BioNTech SE
• Blue Sky Immunotherapies GmbH
• Bristol Myers Squibb Co
• Cellid Co Ltd
• Chain Biotechnology Ltd
• Chengdu Institute of Biological Products Co Ltd
• Cue Biopharma Inc
• Cullinan Oncology LLC
• Elicio Therapeutics Inc
• eTheRNA Immunotherapies NV
• Etubics Corp
• EyeGene Inc
• Genexine Inc
• Gilead Sciences Inc
• GlaxoSmithKline Plc
• Hookipa Pharma Inc
• iBio Inc
• Immunomic Therapeutics Inc
• IMV Inc
• Innovene
• Inovio Pharmaceuticals Inc
• Inthera Bioscience AG
• Iovance Biotherapeutics Inc
• ISA Pharmaceuticals BV
• Ispin Inc
• Merck & Co Inc
• Merck KGaA
• Myrio Therapeutics Pty Ltd
• OncoNano Medicine Inc
• Onconova Therapeutics Inc
• Oxford Vacmedix UK Ltd
• Papivax LLC
• Pathovax LLC
• Pattern Pharma Inc
• PDS Biotechnology Corp
• Precigen Inc
• Privo Technologies Inc
• Rafjik Inc
• Repertoire Immune Medicines Inc
• Rottapharm Biotech Srl
• Rubius Therapeutics Inc
• Shanghai Bovax Biotechnology Co Ltd
• Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
• Shantha Biotechnics Pvt Ltd
• Shuttle Pharmaceuticals Inc
• Sirnaomics Inc
• Symvivo Inc
• TCR Cure Biopharma Technology Co Ltd
• Tessa Therapeutics Ltd
• Theravectys SA
• THEVAX Genetics Vaccine USA Inc
• Touchlight Genetics Ltd
• Transgene SA
• Turnstone Biologics Inc
• UbiVac LLC
• Vaccibody AS
• Vaccitech plc
• Vault Pharma Inc
• Vectorite Biomedical Inc
• ViciniVax BV
• Vir Biotechnology Inc
• Virion Therapeutics LLC
• Virometix AG
• VLP The Vaccines Company SL
• Voltron Therapeutics Inc
• West Lake Biomedical Technology (Hangzhou) Co Ltd
• Xiamen Innovax Biotech Co Ltd

For more information about this report visit https://www.researchandmarkets.com/r/jfbokb

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900